SKIN - Utang jangka dawa perusahaan BeautyHealth

Tandha merek BeautyHealth (SKIN)

The market trend visualized in monetary format on the GURU.Markets platform demonstrates the long-term debt of The Beauty Health (SKIN), which amounts to 0.26. Currently, the HydraFacial brand is restoring its image following technical shortcomings while maintaining customer loyalty. Revenues are based on the sale of cosmetology devices and ancillary serums. US production capacities ensure the output of equipment in high demand within aesthetic medicine worldwide.

The Beauty Health - Utang jangka dawa perusahaan SKIN (periode 04.07.2022 - 31.10.2026)
Produk asil prodhuksi The Beauty Health

For The Beauty Health (SKIN), the company's long-term borrowings reflect the scale of long-term financing for the production of cosmetology devices and the modernization of eco-packaging. This indicator captures the total volume of confirmed credit obligations with a maturity of more than one year. The current value of 0.26 demonstrates the level of debt load, where any sharp deviations signal a large-scale investment cycle or settlements with creditors. The stability of this metric confirms the asset's solvency and the resilience of its business model.

Analisis pesaing The Beauty Health

HCA Inc. (HCA) - Utang jangka dawa|Tenet Healthcare Corporation - Utang jangka dawa perusahaan|FMS - Utang jangka dawa perusahaan|SOLV (Solventum Inc.) - Kewajiban jangka dawa perusahaan|EHC: Gedhene kewajiban jangka dawa|Utang jangka dawa perusahaan Universal Health Services Inc|Kewajiban jangka dawa perusahaan davita.com (DVA)|Utang jangka dawa perusahaan RDNT|OPCH - Utang jangka dawa|Utang jangka dawa perusahaan Surgery Partners Corp SGRY|PINC: Tanggungan utang jangka dawa perusahaan|EYE: Kewajiban jangka dawa perusahaan|progyny.com - Gedhene kewajiban jangka dawa|ARDT (Ardent Health Partners) - Kewajiban jangka dawa perusahaan|SEM: Gedhene kewajiban jangka dawa|ASTH (Apollo Medical Holdings) - Utang jangka dawa perusahaan|MD: Silihan lan utang jangka dawa perusahaan|Utang jangka dawa perusahaan USPH|PNTG - Utang jangka dawa|Organogenesis - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka dawa perusahaan NUTX|Auna Health - Utang jangka dawa perusahaan|SBC: Utang jangka dawa perusahaan|EOLS: Utang jangka dawa perusahaan|Utang jangka dawa chs.net (CYH)|MDWD (MediWound Ltd) - Utang jangka dawa perusahaan|Utang jangka dawa perusahaan Biote|Kewajiban jangka dawa perusahaan JYNT (The Joint Corporation)|Utang jangka dawa perusahaan DocGo, Inc (DCGO)|P3 Health Partners - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka dawa GANX (Gain Therapeutics Inc.)|EUDA: Kewajiban jangka dawa perusahaan|Utang jangka dawa Basel Medical Group|CLGN (collplant.com) - Kewajiban jangka dawa perusahaan|Cuprina Holdings Limited - Silihan lan utang jangka dawa perusahaan|CCM (Concord Medical Services) - Utang jangka dawa perusahaan|AMS: Silihan lan utang jangka dawa perusahaan|Utang jangka dawa perusahaan MRM|ALBT - Utang jangka dawa|Utang jangka dawa perusahaan DHAI (DIH Holding US Inc.)|Utang jangka dawa perusahaan Carmell Corp XAGE|NIVF - Utang jangka dawa perusahaan|ATIP: Utang jangka dawa perusahaan|CMAX (CareMax) - Kewajiban jangka dawa perusahaan|KDLY: Gedhene kewajiban jangka dawa|MODV (LogistiCare) - Utang jangka dawa perusahaan|NVOS: Silihan lan utang jangka dawa perusahaan|Utang jangka dawa perusahaan SunLink Health Systems (SSY)|Gunggunge utang jangka dawa imacholdings.comm